Themes / Group
Inactive · established relationshipLatest completed snapshot · Aug 21 · 16:11 ET

MARKET-DISCOVERED GROUP

Clinical Biopharmaceuticals

THE TRADER READRecurring relationship, inactive in the latest snapshot

7 of 12 measured session-normalized paths align to the upside across 5.6 effective names. Common-bar coverage spans 12 of 16 cohort members. Capital-flow agreement is 16%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth10 up · 6 down+1.0% session-normalized median path
Capital-flow alignment16%Price breadth is not yet confirmed by flow
Activity nowCalmActivity score 31/100 · lift 0.8×
Evidence depth2 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

4 timed events · 15:40–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. 5-minute inferenceEWTX registered the first material upside path

    +0.61% session path at the threshold · EWTX

  2. 5-minute inferenceAXSM registered a material upside path

    +0.46% session path at the threshold · AXSM

  3. 5-minute inferenceALMS registered a material upside path

    +7.45% session path at the threshold · ALMS

  4. 5-minute inferenceGPCR registered a material downside path

    -1.36% session path at the threshold · GPCR

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

Session-normalized 5m paths

Observed movement is balanced across 5.6 effective names. ALMS represents 34.1% of absolute path energy; 7 of 12 members align with the up relative path.

ConstructionBalanced34.1% from the largest path
Effective names5.6 / 1212 of 16 cohort members had common bars
Direction breadth7/12 alignedupside relative path · 1 counter-moving
Largest moverALMS 34.1%47.4% from the top two paths
ALMS34.1%Dominant mover · path +7.72% · basket +0.64pp
GPCR13.3%Counter-move · path -3.00% · basket -0.25pp
PRAX12.7%Aligned contributor · path +2.87% · basket +0.24pp
RCUS9.8%Aligned contributor · path +2.22% · basket +0.18pp
EWTX9.5%Aligned contributor · path +2.16% · basket +0.18pp
MAZE7.2%Aligned contributor · path +1.62% · basket +0.14pp
TYRA4.6%Aligned contributor · path +1.05% · basket +0.09pp
DNTH4.2%Aligned contributor · path +0.95% · basket +0.08pp
CYTK1.6%Flat / inactive path · path -0.36% · basket -0.03pp
AXSM1.5%Flat / inactive path · path +0.35% · basket +0.03pp
LNTH1.1%Flat / inactive path · path -0.24% · basket -0.02pp
SNDX0.5%Flat / inactive path · path -0.10% · basket -0.01pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. EWTX moved higher firstFirst member to clear the material path threshold · path +0.61%
  2. AXSM registered a material higher path0m after the first price move · path +0.46%
  3. ALMS registered a material higher path1395m after the first price move · path +7.45%
  4. GPCR registered a material lower path1395m after the first price move · path -1.36%
  5. PRAX registered a material higher path1395m after the first price move · path +3.38%
  6. RCUS registered a material higher path1395m after the first price move · path +1.53%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

Session-normalized
Aug 20 · 15:40 ETMove visible 15:05 ETAug 21 · 15:55 ET
Group median +1.00%Strongest relative path ALMSWeakest relative path GPCR

Observed member paths normalized to the session. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

No high-confidence shared filing driver is available. The market relationship is observed, but the cause remains unexplained.

CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

NBIXNot confirming

GPCR · text peer

JAZZNot confirming

XENE · text peer

CMPSNot confirming

PRAX · text peer

OMERNot confirming

AXSM · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
RCUSMAZEALMSXENEDNTHGPCRVERACYTKAXSMSNDXPRAXTYRAVRDNLNTHWVEEWTX

10/16 active10 rising · 6 falling

MemberUnusual activityToday's moveRead now
RCUSArcus Biosciences, Inc.
Elevated · 100/100
+2.9%
Aligned price + flowActive in 31.8% of observed group sessions
MAZEMaze Therapeutics, Inc.
Most unusual · 98/100
+1.7%
Aligned path contributorActive in 27.3% of observed group sessions
ALMSAlumis Inc.
Elevated · 92/100
+5.9%
Dominant path moverActive in 22.7% of observed group sessions
XENEXenon Pharmaceuticals Inc.
Elevated · 83/100
+1.9%
Active; unclassifiedActive in 27.3% of observed group sessions
DNTHDianthus Therapeutics, Inc.
Elevated · 78/100
+1.3%
Aligned path contributorActive in 31.8% of observed group sessions
GPCRStructure Therapeutics Inc.
Elevated · 77/100
-2.5%
Counter-move / dispersionActive in 27.3% of observed group sessions
VERAVera Therapeutics, Inc.
Elevated · 72/100
+3.4%
Flow confirmerActive in 4.5% of observed group sessions
CYTKCytokinetics, Incorporated
Elevated · 71/100
-0.4%
Active; unclassifiedActive in 22.7% of observed group sessions
AXSMAxsome Therapeutics, Inc.
Elevated · 65/100
-0.2%
Flow divergenceActive in 13.6% of observed group sessions
SNDXSyndax Pharmaceuticals, Inc.
Elevated · 65/100
-0.5%
Active; unclassifiedActive in 40.9% of observed group sessions
PRAXPraxis Precision Medicines, Inc.
Elevated · 60/100
+3.1%
Aligned price + flowActive in 18.2% of observed group sessions
TYRATyra Biosciences, Inc.
Quiet · 51/100
+1.6%
Watch / laggardActive in 31.8% of observed group sessions
VRDNViridian Therapeutics, Inc.
Quiet · 47/100
-0.9%
Watch / laggardActive in 22.7% of observed group sessions
LNTHLantheus Holdings, Inc.
Quiet · 44/100
-0.3%
Watch / laggardActive in 13.6% of observed group sessions
WVEWave Life Sciences, Inc.
Quiet · 42/100
+0.8%
Watch / laggardActive in 4.5% of observed group sessions
EWTXEdgewise Therapeutics, Inc.
Quiet · 37/100
+2.0%
Watch / laggardActive in 27.3% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
RCUSArcus Biosciences, Inc.Participating+2.9%31.8% of 22 sessionsPrice participation with accumulating signed flow.
MAZEMaze Therapeutics, Inc.Most unusual+1.7%27.3% of 22 sessionsMost unusual activity in this snapshot; performance direction may differ.
ALMSAlumis Inc.Participating+5.9%22.7% of 22 sessionsPrice participation is not yet confirmed by per-name flow.
XENEXenon Pharmaceuticals Inc.Participating+1.9%27.3% of 22 sessionsPrice participation is not yet confirmed by per-name flow.
DNTHDianthus Therapeutics, Inc.Participating+1.3%31.8% of 22 sessionsPrice participation is not yet confirmed by per-name flow.
GPCRStructure Therapeutics Inc.Participating-2.5%27.3% of 22 sessionsPrice participation is not yet confirmed by per-name flow.
VERAVera Therapeutics, Inc.Participating+3.4%4.5% of 22 sessionsPrice participation with accumulating signed flow.
CYTKCytokinetics, IncorporatedParticipating-0.4%22.7% of 22 sessionsPrice participation is not yet confirmed by per-name flow.
AXSMAxsome Therapeutics, Inc.Participating-0.2%13.6% of 22 sessionsPrice participation with distributing signed flow.
SNDXSyndax Pharmaceuticals, Inc.Participating-0.5%40.9% of 22 sessionsPrice participation is not yet confirmed by per-name flow.
PRAXPraxis Precision Medicines, Inc.Participating+3.1%18.2% of 22 sessionsPrice participation with accumulating signed flow.
TYRATyra Biosciences, Inc.Quiet / lagging+1.6%31.8% of 22 sessionsNot participating yet; a breadth test or a genuine divergence.
VRDNViridian Therapeutics, Inc.Quiet / lagging-0.9%22.7% of 22 sessionsNot participating yet; a breadth test or a genuine divergence.
LNTHLantheus Holdings, Inc.Quiet / lagging-0.3%13.6% of 22 sessionsNot participating yet; a breadth test or a genuine divergence.
WVEWave Life Sciences, Inc.Quiet / lagging+0.8%4.5% of 22 sessionsNot participating yet; a breadth test or a genuine divergence.
EWTXEdgewise Therapeutics, Inc.Quiet / lagging+2.0%27.3% of 22 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Early observed follow-through

4/4 events completed
30 minutes+0.18%67% continuation · n=3Median MFE +0.37% · MAE -0.88%
60 minutes-0.47%33% continuation · n=3Median MFE +0.37% · MAE -0.88%
Session close+0.34%100% continuation · n=2Median MFE +0.90% · MAE -0.84%
Next-session close+0.14%67% continuation · n=3Median MFE +0.37% · MAE -0.88%
Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 2 completed episodes across 22 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support28 daysHow often the cohort identity was observed
Completed episodes2Separate periods of broad group activity
Active sessions22Completed session observations, not trades
2026-08-19 → 2026-08-202 active sessions25% composition consistency through the episode
2026-07-13 → 2026-08-1320 active sessionsNo name was active through every recorded session
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
SNDX40.9% · 1 episode
DNTH31.8% · 2 episodes
RCUS31.8% · 2 episodes
TYRA31.8% · 1 episode
EWTX27.3% · 1 episode
GPCR27.3% · 2 episodes
MAZE27.3% · 1 episode
XENE27.3% · 2 episodes
ALMS22.7% · 2 episodes
CYTK22.7% · 1 episode
VRDN22.7% · 2 episodes
PRAX18.2% · 2 episodes
AXSM13.6% · 1 episode
LNTH13.6% · 2 episodes
VERA4.5% · 1 episode
WVE4.5% · 1 episode